APP Pharma prepares for US launch of Hycamtin generic
This article was originally published in Scrip
Executive Summary
APP Pharmaceuticals, a subsidiary of Fresenius Kabi Pharmaceuticals, says the US FDA has cleared its topotecan injection, a generic version of GlaxoSmithKline's anticancer Hycamtin, for marketing and the firm plans to launch it immediately.